1,005K shares changed hands by the end of trading on Wednesday. Volume was up 85.04% over the stocks average daily volume.
Traders are more bullish of late if you put credence in the decrease in short interest. The company had a fall in short interest between September 29, 2017 and October 13, 2017 of -17.90%. Short interest decreased from 1,883,046 to 1,545,940 over that period. The days to cover decreased to 2.0 and the percentage of shorted shares is 0.03% as of October 13.
Here is a rundown on some insider market activity for Biodelivery Sci Intl (NASDAQ:BDSI). Mark A. Sirgo, President and CEO sold $569,886 worth of shares at a price of $2.83 on September 21st. The President and CEO now owns $4,271,211 of the stock as recorded in a recent Form 4 SEC filing.
These firms have modified their investment in BDSI. As of quarter end A.r.t. Advisors, LLC had bought 44,700 shares growing its position 167.1%. The value of the company’s investment in Biodelivery Sci Intl increased from $74,000 to $210,000 a change of 183.8% for the reporting period. Krilogy Financial LLC augmented its stake by buying 30,000 shares an increase of 28.8% in the quarter. Krilogy Financial LLC owns 134,000 shares worth $395,000. The total value of its holdings increased 35.7%.
Renaissance Technologies LLC added to its investment by buying 94,500 shares an increase of 19.3% as of 09/30/2017. Renaissance Technologies LLC now controls 585,200 shares valued at $1,726,000. The value of the position overall is up by 25.6%. As of the end of the quarter Stonepine Capital Management, LLC had acquired a total of 389,727 shares growing its holdings by 11.2%. The value of the investment in Biodelivery Sci Intl went from $9,737,000 to $11,409,000 a change of $1,672,000 since the last quarter.
On October 22, 2017 Piper Jaffray Companies released research on BDSI with a rating of “Buy” and a price target of $4.00. HC Wainwright updated its forecast on BDSI stating a rating of “Buy” and setting a price target of $5.00.
On October 12 analysts at Roth Capital updated guidance on BDSI and giving a rating of “Buy” and projecting a price target of $5.00. Equity analyst Cantor Fitzgerald updated coverage of BDSI with a rating of “Buy” and price target of $5.00.
On September 10 analysts at HC Wainwright issued a report on BDSI with a rating of “Buy”. August 20 investment analysts at Cantor Fitzgerald reiterated a “Overweight” rating on the stock.
The company is trading up by 1.59% percent from yesterday’s close. The P/E ratio is 23.86 and the market value is 124.90M. As of the last earnings report the EPS was $0.09 with 55.88M shares presently outstanding.
BioDelivery Sciences International, Inc., launched on April 18, 2002, is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Business’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Business’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology..